



**AZORA**

## **AZORA ADDS CARLOS BARALLOBRE TO ITS BOARD TO STRENGTHEN ITS GROWTH STRATEGY**

- **The management company strengthens its governing body by adding the former CEO of Italfarmaco and former Managing Partner of Mercapital to enhance its capabilities in operational management, Private Equity, and international growth**
- **The appointment comes at a time of strong expansion for Azora across its various investment platforms.**

**Madrid, 30 March 2026** – The Board of Azora Capital has been strengthened with the appointment of Carlos Barallobre, with the aim of enhancing its capabilities in operational management, private equity, and international growth, at a time of strong expansion of the firm across its various investment platforms.

The new board member, who will also serve as board member of Azora Gestión SGIC and will join the Committee on Infrastructure, Energy and Direct Investment, brings a long professional career spanning more than three decades.

Between 2014 and 2025, he served as CEO of the international pharmaceutical group Italfarmaco, which operates in more than 90 countries and has 4,100 employees. Under his leadership, the company tripled its revenue to reach €1.7 billion, driven by an ambitious expansion in Europe and the United States and by its entry into new business segments such as rare diseases and *Consumer Healthcare*.

Anteriormente desarrolló su carrera profesional en Mercapital (actualmente Alantra Private Equity), donde trabajó durante más de 20 años y llegó a ocupar el cargo de Managing Partner. En esta firma lideró numerosas operaciones de *growth*, *buy-out* y *buy & build*, entre las que destacan Clece, Gasmedi, USP Hospitales, Grupo Hospiten y Grupo Hospitalario Quirón.

Previously, he developed his career at Mercapital (now Alantra Private Equity), where he worked for over 20 years and rose to the position of Managing Partner. At that firm, he led numerous *growth*, *buy-out*, and *buy-&-build* transactions, including Clece, Gasmedi, USP Hospitales, Grupo Hospiten, and Grupo Hospitalario Quirón.

Currently, Carlos Barallobre is a member of the Board of Directors of Italfarmaco Spain and ITF Therapeutics USA.

He holds an MBA from INSEAD and a degree in Economics and Business Administration from ICADE.

### **Para más información:**

#### **Gabinete de prensa de Azora**

Nacho Miquel: [nacho.miquel@irazustacomunicacion.com](mailto:nacho.miquel@irazustacomunicacion.com)

Alberto Rodríguez: [alberto.rodriguez@irazustacomunicacion.com](mailto:alberto.rodriguez@irazustacomunicacion.com)



**AZORA**

Teléfono: +34 91 563 41 79

### **Sobre Azora**

Azora Capital, que opera en los mercados paneuropeo y estadounidense de activos reales, es una gestora de inversiones alternativas líder, con 14.600 millones de euros en activos bajo gestión. Azora lleva más de 20 años desarrollando y gestionando con éxito estrategias de inversión de valor añadido basadas en las megatendencias mundiales, con especial foco en activos intensivos en operaciones. Hasta la fecha, Azora ha logrado una TIR neta combinada del 19% en todas sus inversiones, aprovechando su experiencia para ofrecer a los inversores una generación de valor y alfa excepcionales a largo plazo.

Azora fue fundada en 2003 por Concha Osácar y Fernando Gumuzio y emplea a más de 600 profesionales en tres oficinas en Europa y Estados Unidos. Azora se enorgullece de su cultura integradora y emprendedora, y de su visión para convertirse en una fuerza de cambio en el mundo a través de su compromiso con los más altos niveles de sostenibilidad medioambiental y social.

Para más información, visite: <https://www.azora.com>